RecruitingPhase 2NCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eastern Cooperative Oncology Group
Principal Investigator
Shira Dinner, MD
Northwestern University
Intervention
Daratumumab / Hyaluronidase Injection(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (1)

Collaborators

Janssen, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05289687 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials